• Customer Login
  • Search
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
    • Zimeta™ (dipyrone injection)
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Pipeline
  • Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • epoCat™ (feline recombinant erythropoietin)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu
News
You are here: Home / News / Future Events / No Events Currently Scheduled

No Events Currently Scheduled

February 12, 2013/in Future Events /by Russell Radefeld
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Russell Radefeld /wp-content/uploads/2017/09/KindredBioHeader2017.png Russell Radefeld2013-02-12 22:25:522016-02-12 22:27:50No Events Currently Scheduled

KindredBio News

  • Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies
  • Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in Dogs
  • Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
  • Kindred Biosciences Receives FDA Approval of Zimeta™ (dipyrone injection) for the Control of Pyrexia in Horses
  • Event: Kindred Biosciences to Present at Stifel Healthcare Conference

News Archives

  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • August 2015
  • May 2015
  • March 2015
  • December 2014
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • December 2013
  • August 2013
  • July 2013
  • March 2013
  • February 2013
  • January 2013

News

  • Kindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesJanuary 8, 2020 - 4:04 pm
  • Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsDecember 16, 2019 - 8:04 am
  • Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight LossDecember 12, 2019 - 9:09 am

Events

  • Event: Kindred Biosciences to Present at Stifel Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Participate at Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:11 pm
  • Event: Kindred Biosciences to Announce Third Quarter 2019 Financial ResultsOctober 28, 2019 - 8:35 am
$9.50 Stock is Down -0.16 (-1.66%)
KIN (Common Stock)
Previous Close Volume
$9.66 89,150
Intraday High Intraday Low
$9.83 $9.35
52 Week High 52 Week Low
$11.35 $5.96
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

© Copyright 2012-2019 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
KindredBio Announces Filing of an Investigational New Animal Drug Application... KindredBio Announces the Filing of an INAD for Laminitis in Horses
Scroll to top